Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Satellos BioscienceTSX:MSCL +1.14%37 3-Year EBITDA Growth Rate is 12.20% as of Mar. 2026, which is at its 10-year median of 12.20. GuruFocus rates TSX:MSCL with a GF Score™ of 37/100. The stock has 1 warning sign investors should review. Among 1,136 Biotechnology companies, Satellos Bioscience ranks worse than 53.52% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 12.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -13.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Satellos Bioscience was 25.00% per year. The lowest was -56.90% per year. And the median was 12.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Satellos Bioscience 3-Year EBITDA Growth Rate Related Terms
TSX:MSCL vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Satellos Bioscience's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Satellos Bioscience 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Satellos Bioscience's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Satellos Bioscience's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 12.20% mean?
Satellos Bioscience (TSX:MSCL) has a 3-Year EBITDA Growth Rate of 12.20% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Satellos Bioscience and its competitors. This is near median its historical median of 12.20. According to the industry distribution chart, Satellos Bioscience ranks #608 out of 1136 companies in the Biotechnology industry, placing it in the top 53.5%.
Is Satellos Bioscience's 3-Year EBITDA Growth Rate too high?
Satellos Bioscience's current 3-Year EBITDA Growth Rate of 12.20% is near median its 10-year median of 12.20. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Satellos Bioscience's value of 12.20% is 17.8% below this industry median. Based on the distribution chart, Satellos Bioscience ranks #608 out of 1136 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Satellos Bioscience has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Satellos Bioscience's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Satellos Bioscience ranks #608 out of 1136 companies for 3-Year EBITDA Growth Rate. This places Satellos Bioscience in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.85. Satellos Bioscience's value of 12.20% is 17.8% below this benchmark. While the company's 10-year median is 12.20 vs. the industry median of 14.85, Satellos Bioscience has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,136 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Satellos Bioscience's current 3-Year EBITDA Growth Rate of 12.20% is 17.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Satellos Bioscience and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Satellos Bioscience's current 3-Year EBITDA Growth Rate is 12.20%, which is near median its own 10-year median of 12.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Satellos Bioscience stock overvalued right now?
Satellos Bioscience (TSX:MSCL) has a current 3-Year EBITDA Growth Rate of 12.20%. The current 3-Year EBITDA Growth Rate is 12.20%, which is near median its 10-year median of 12.20 and 17.8% below the Biotechnology industry median of 14.85. Satellos Bioscience's overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Satellos Bioscience (TSX:MSCL), the current 3-Year EBITDA Growth Rate is 12.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.
37GF Score
Get the complete analysis for TSX:MSCL
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:MSCL has been successfully added to your 
